TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was up 15.2% on Thursday . The stock traded as high as $1.67 and last traded at $1.67. Approximately 225 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 4,498 shares. The stock had previously closed at $1.45.
TriSalus Life Sciences Price Performance
The stock has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.22.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Industrial Products Stocks Investing
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What is Short Interest? How to Use It
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
